<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               6 ADVERSE REACTIONS<BR>               <BR>                  The following adverse reactions are discussed in greater detail in other sections of the labeling:<BR>                  <BR>                     Serious and sometimes fatal hypersensitivity reaction. In one trial, once-daily dosing of abacavir was associated with more severe hypersensitivity reactions [see Boxed Warning, Warnings and Precautions (5.1)].<BR>                     Lactic acidosis and severe hepatomegaly [see Boxed Warning, Warnings and Precautions (5.2)].<BR>                     Acute exacerbations of hepatitis B [see Boxed Warning, Warnings and Precautions (5.3)].<BR>                     Hepatic decompensation in patients co-infected with HIV-1 and Hepatitis C [see Warnings and Precautions (5.4)].<BR>                     Immune reconstitution syndrome [see Warnings and Precautions (5.5)].<BR>                     Fat redistribution [see Warnings and Precautions (5.6)].<BR>                     Myocardial infarction [see Warnings and Precautions (5.7)].<BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        The most commonly reported adverse reactions of at least moderate intensity (incidence >5%) in an adult HIV-1 clinical trial were drug hypersensitivity, insomnia, depression/depressed mood, headache/migraine, fatigue/malaise, dizziness/vertigo, nausea, and diarrhea. (6.1)<BR>                        <BR>                           To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.<BR>                        <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.1 Clinical Trials Experience<BR>                     <BR>                        Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.<BR>                        <BR>                           Therapy-Naive Adults: Treatment-emergent clinical adverse reactions (rated by the investigator as moderate or severe) with a ≥5% frequency during therapy with ZIAGEN 600 mg once daily or ZIAGEN 300 mg twice daily, both in combination with lamivudine 300 mg once daily and efavirenz 600 mg once daily, are listed in Table 1.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Refid_392c3213-abc1-489c-8cc1-f7612a095"><BR>                           <caption>Table 1. Treatment-Emergent (All Causality) Adverse Reactions of at Least Moderate Intensity (Grades 2-4, &#8805;5% Frequency) in Therapy-Naive Adults (CNA30021) Through 48 Weeks of Treatment</caption><BR>                           <col width="45%"/><BR>                           <col width="35%"/><BR>                           <col width="35%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <paragraph>Adverse Event</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>ZIAGEN 600 mg q.d.</paragraph><BR>                                    <paragraph>plus EPIVIR plus Efavirenz</paragraph><BR>                                    <paragraph>(n&#160;=&#160;384)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>ZIAGEN 300 mg b.i.d.</paragraph><BR>                                    <paragraph>plus EPIVIR plus Efavirenz</paragraph><BR>                                    <paragraph>(n&#160;=&#160;386)</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph><BR>                                       <content styleCode="bold">Drug hypersensitivity</content><BR>                                       <sup>a,b</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>9%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>7%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Insomnia</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>7%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>9%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Depression/Depressed mood</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>7%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>7%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Headache/Migraine </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>7%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>6%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Fatigue/Malaise</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>6%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>8%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Dizziness/Vertigo </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>6%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>6%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Nausea</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>5%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>6%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Diarrhea<sup>a</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>5%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>6%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Rash</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>5%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>5%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Pyrexia</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>5%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>3%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Abdominal pain/gastritis</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>4%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>5%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule "><BR>                                    <paragraph>Abnormal dreams</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>4%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule "><BR>                                    <paragraph>5%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Anxiety</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>3%</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>5%</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td colspan="3" styleCode="Rrule Lrule "><BR>                                    <paragraph><BR>                                       <sup>a</sup>Subjects receiving ZIAGEN 600 mg once daily, experienced a significantly higher incidence of severe drug hypersensitivity reactions and severe diarrhea compared with subjects who received ZIAGEN 300 mg twice daily. Five percent (5%) of subjects receiving ZIAGEN 600 mg once daily had severe drug hypersensitivity reactions compared with 2% of subjects receiving ZIAGEN 300 mg twice daily. Two percent (2%) of subjects receiving ZIAGEN 600 mg once daily had severe diarrhea while none of the subjects receiving ZIAGEN 300 mg twice daily had this event.</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td colspan="3" styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph><BR>                                       <sup>b</sup>CNA30024 was a multi-center, double-blind, controlled trial in which 649 HIV-1-infected, therapy-naive adults were randomized and received either ZIAGEN (300 mg twice daily), EPIVIR (150 mg twice daily), and efavirenz (600 mg once daily); or zidovudine (300 mg twice daily), EPIVIR (150&#160;mg twice daily), and efavirenz (600 mg once daily). CNA30024 used double-blind ascertainment of suspected hypersensitivity reactions. During the blinded portion of the trial, suspected hypersensitivity to abacavir was reported by investigators in 9% of 324 patients in the abacavir group and 3% of 325 patients in the zidovudine group.</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR><BR>                           Laboratory Abnormalities: Laboratory abnormalities observed in clinical trials of ZIAGEN were anemia, neutropenia, liver function test abnormalities, and elevations of CPK, blood glucose, and triglycerides. Additional laboratory abnormalities observed in clinical trials of EPIVIR were thrombocytopenia and elevated levels of bilirubin, amylase, and lipase.<BR>                        The frequencies of treatment-emergent laboratory abnormalities were comparable between treatment groups in CNA30021.<BR>                        <BR>                           Other Adverse Events: In addition to adverse reactions listed above, other adverse events observed in the expanded access program for abacavir were pancreatitis and increased GGT.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     6.2 Postmarketing Experience<BR>                     <BR>                        In addition to adverse reactions reported from clinical trials, the following reactions have been identified during postmarketing use of abacavir, lamivudine, and/or EPZICOM. Because they are reported voluntarily from a population of unknown size, estimates of frequency cannot be made. These reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to abacavir, lamivudine, and/or EPZICOM.<BR>                        <BR>                           Abacavir: <BR>                           Cardiovascular: Myocardial infarction.<BR>                        <BR>                           Skin: Suspected Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) have been reported in patients receiving abacavir primarily in combination with medications known to be associated with SJS and TEN, respectively. Because of the overlap of clinical signs and symptoms between hypersensitivity to abacavir and SJS and TEN, and the possibility of multiple drug sensitivities in some patients, abacavir should be discontinued and not restarted in such cases.<BR>                        There have also been reports of erythema multiforme with abacavir use.<BR>                        <BR>                           Abacavir and Lamivudine: <BR>                           Body as a Whole: Redistribution/accumulation of body fat [see Warnings and Precautions (5.6)].<BR>                        <BR>                           Digestive: Stomatitis.<BR>                        <BR>                           Endocrine and Metabolic: Hyperglycemia.<BR>                        <BR>                           General: Weakness.<BR>                        <BR>                           Hemic and Lymphatic: Aplastic anemia, anemia (including pure red cell aplasia and severe anemias progressing on therapy), lymphadenopathy, splenomegaly.<BR>                        <BR>                           Hepatic: Lactic acidosis and hepatic steatosis [see Warnings and Precautions (5.2)], posttreatment exacerbation of hepatitis B [see Warnings and Precautions (5.3)].<BR>                        <BR>                           Hypersensitivity: Sensitization reactions (including anaphylaxis), urticaria.<BR>                        <BR>                           Musculoskeletal: Muscle weakness, CPK elevation, rhabdomyolysis.<BR>                        <BR>                           Nervous: Paresthesia, peripheral neuropathy, seizures.<BR>                        <BR>                           Respiratory: Abnormal breath sounds/wheezing.<BR>                        <BR>                           Skin: Alopecia, erythema multiforme, Stevens-Johnson syndrome.<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>